
|Articles|June 1, 2001 (Updated: November 15, 2020)
- Pharmaceutical Executive-06-01-2001
- Volume 0
- Issue 0
Rx-to-OTC: Unwanted Attention
Author(s)Kevin Gopal
Washington, DC-An FDA advisory committee voted overwhelmingly to recommend that Claritin (loratadine), Allegra (fexofenadine), and Zyrtec (cetirizine) be changed from prescription to over-the-counter products. Although the vote is not binding, FDA usually follows such panels’ recommendations.
Advertisement
Articles in this issue
over 24 years ago
Industry Under Investigationover 24 years ago
Emotion - The New Brand Integratorover 24 years ago
For Love of the Gameover 24 years ago
Field of Dreamsover 24 years ago
Workshop: Access Optionsover 24 years ago
Emotion - The New Brand Integratorover 24 years ago
Emotion - Biotech Renaissance Manover 24 years ago
Relocation: Coming to Americaover 24 years ago
Stocks: Catching the Market Bluesover 24 years ago
Gathering LightNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Bringing HIV Prevention DTC: Q&A with Ashley Gildea
3
FDA Approves Hernexeos Under National Priority Voucher Program
4
Leading in the Psychedelic Space: Q&A with Tarek Rabah
5




